Hers vs Found: Subscription Models and Compounded GLP-1

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Welcome to the PlexusDx Education Hub, where we translate GLP-1 science, weight-management options, and the genetics beneath them into decisions you can actually use. Explore the full Peptides & GLP-1 library.

Independent editorial content follows. PlexusDx maintains no affiliate relationship, sponsorship, or commercial arrangement with Hers, Found, or their parent companies.

Full head-to-head: PlexusDx vs Found →

Hers and Found both wrap GLP-1 access inside a subscription, but the day-to-day experience of a program, not the drug, is what most people are actually comparing. This review looks at how each is built, how the compounded pathway works, what the trials say, and the genetic dimension that sits outside any subscription. Market context reflects April 2026.

Two subscription programs, side by side

Hers (Hims & Hers Health) runs as subscription telehealth: a virtual evaluation, a provider prescription, and either brand-name FDA-approved dispensing or compounded semaglutide or tirzepatide through a licensed compounding pharmacy. Found also operates as subscription telehealth, with its own program structure, medication menu, and pricing. Because both wrap ongoing membership around the prescription, the real differences live in provider access, follow-up, support tools, and how each handles the compounded route.

How the compounded pathway fits in

When a program dispenses compounded semaglutide or tirzepatide rather than a brand product, it relies on a licensed 503A compounding pharmacy. That pathway is a legitimate part of both models, and it is one reason monthly totals vary: compounded dispensing carries a different cost and supply profile than brand-name fulfillment. Neither Hers nor Found changes the underlying compound by choosing this route; they change the packaging, price, and availability around it.

The pharmacology both programs share

Found and Hers prescribe from the same class. GLP-1 receptor agonists, including semaglutide, liraglutide, and dulaglutide, and the GIP/GLP-1 dual agonist tirzepatide, act on appetite regulation, satiety, and gastric emptying. A subscription platform delivers that pharmacology; it does not alter it. The mechanism you experience is a property of the molecule, whichever brand's app you log into.

What the trials established

The evidence sits with the compound class, not the subscription. Semaglutide for weight management was studied in STEP (NEJM 2021), tirzepatide in SURMOUNT (NEJM 2022), and tirzepatide for obstructive sleep apnea in SURMOUNT-OSA (NEJM 2024). Effect sizes depend on dose, compound, and population. A coaching layer or app experience does not add to or subtract from that clinical record.

The variable no subscription includes

What a membership never maps is your genetics. Variants in GLP1R, the GLP-1 receptor gene that is the direct target of every GLP-1 compound, along with FTO, MC4R, and TCF7L2, describe the metabolic terrain a clinician prescribes into. These markers are pathway-level. They do not predict response to any specific medication, but they do give shape to the biology a subscription otherwise treats as a blank slate.

The PlexusDx Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights, covering FTO, MC4R, and TCF7L2. Alongside the PlexusDx Weight Management Protocols, which offer Semaglutide Injection at $189 and Tirzepatide Injection at $289 month to month, it makes the case for a test before you invest sequence, so your subscription decision starts from your biology.

No affiliation: PlexusDx has no commercial relationship with Hers or Found and does not represent either company.

More from the Education Hub: GLP 1 What Is and GLP 1 Receptor Agonist.

Disclaimer: This comparison is educational. PlexusDx is not affiliated with Hers or Found. PlexusDx offers semaglutide and tirzepatide through its own Weight Management Protocols. The Precision Peptide Genetic Test analyzes how your genes influence peptide-related biological pathways and does not predict response to any specific medication. Consult a qualified healthcare provider before beginning any peptide protocol.

Frequently Asked Questions

How do the Hers and Found subscription models differ?

Both are subscription telehealth, so the differences are in the wrapper: provider access, follow-up cadence, support tools, medication menu, and pricing tiers. Neither changes the underlying pharmacology. Review each brand's current program details directly, since the value of a subscription depends heavily on how often you actually use the support it bundles.

What does the compounded pathway mean for me?

It means your semaglutide or tirzepatide is prepared by a licensed 503A compounding pharmacy rather than dispensed as a brand-name product. Both Hers and Found may use this route. It affects cost, packaging, and availability, but not the compound's mechanism, which is fixed by the molecule itself.

Does the Precision Peptide Genetic Test replace a subscription?

No. It is upstream context, not a program. The test maps pathway-level variants such as FTO, and MC4R that describe your baseline GLP-1 biology. It does not predict medication response, but it informs the conversation you have with a provider before choosing any subscription.

Keep learning at the PlexusDx Education Hub. Return to the Peptides & GLP-1 library.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.